股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 綠新生物科技有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01084 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法定 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 綠新生物科技有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01084 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法 ...

致：香港交易及結算所有限公司 公司名稱: 綠新生物科技有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01084 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 ...

致：香港交易及結算所有限公司 公司名稱: 緑新親水膠軆海洋科技有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01084 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 股份發行人及根據《 ...

致：香港交易及結算所有限公司 公司名稱: 緑新親水膠軆海洋科技有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01084 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月3 ...

GREEN FRESH BIOTECHNOLOGY COMPANY LIMITED 綠新生物科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：01084) 通 知 信 函 請注意，所有未來公司通訊的英文版和中文版將在本公司網站 www.greenfreshfood.com 和香港交易所網站 www.hkexnews.hk 上提供。 本公司將透過電子郵件 或郵寄方式向 閣下發送英文及中文之發布公司通訊的通知函。 作為非登記股東，如有意根據《上市規則》收取公司通訊， 閣下應聯絡代 閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有 限公司（統稱「中介公司」），並向 閣下的中介公司提供 閣下的電子郵件地址或郵寄地址。 如果本公司沒有從中介公司收到 閣下的有效電子郵件地址或郵寄地址，直至中介公司收到 閣下有效的電子郵件地址或郵寄地址前， 閣下或(i)無法收到 任何有關發布公司通訊的通知；及(ii)需要主動查看本公司網站和香港交易所網站以留意公司通訊的發 ...

（於開曼群島註冊成立的有限公司） (Stock code 股份代號：01084) 通 知 信 函 各位登記股東： 綠新生物科技有限公司（「本公司」） – 2025 年中期報告（「本次公司通訊文件」）之發佈通知 本公司的本次公司通訊文件備有中、英文版本，並已上載於香港聯合交易所有限公司（「香港交易所」）網站（www.hkexnews.hk）及本公司網 站（www.greenfreshfood.com），歡迎瀏覽。 閣下若因任何理由以致在收取或接收載於本公司網址上的本次公司通訊文件出現困難， 閣下可 將要求（註明 閣下的姓名、地址及要求）以電郵方式發送到本公司之電郵地址 greenfreshfood.ecom@computershare.com.hk 或以書面方式郵寄致 本公司的香港股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。本公司將於接到 閣 下通知後，盡快向 閣下免費發送有關本次公司通訊文件的印刷本。 以電子方式發布公司通訊之安排 根據自 2023 年 12 月 31 日起生效的擴大無紙化制度及以電子方式發布公司通訊規定下香港聯合交易所有 ...

Revenue and Sales Performance - For the first half of 2025, the company's revenue was RMB 410.0 million, a decrease of 10.7% compared to RMB 459.0 million in the first half of 2024[12]. - The total revenue from carrageenan and agar products accounted for 75.8% of the company's total revenue, a decrease of 3.0% from the first half of 2024[12]. - Sales volume and average selling prices of refined carrageenan decreased by approximately 4.2% and 5.5%, respectively, compared to the first half of 2024[11]. - Sales volume and average selling prices of agar decreased by approximately 12.8% and 1.8%, respectively, compared to the same period last year[11]. - The decline in revenue was primarily due to decreased sales volume and prices of carrageenan and agar products[12]. - Revenue from the Chinese market in the first half of 2025 was RMB 189.3 million, a decrease of RMB 56.6 million or 23.0% compared to the first half of 2024[14]. - Revenue from overseas markets in the first half of 2025 was RMB 220.7 million, a decrease of RMB 7.6 million or 3.6% compared to the first half of 2024[14]. - The sales revenue of carrageenan and agar accounted for 75.8% of the group's total revenue, a decrease of 3.0% compared to the first half of 2024[19]. - The company anticipates a recovery in global demand for hydrophilic colloid products as geopolitical tensions ease, with stable sales performance expected in China[16]. Profitability and Financial Performance - In the first half of 2025, the group's gross profit was RMB 60.1 million, a decrease of RMB 38.7 million or 39.2% compared to the first half of 2024[21]. - The overall gross margin for the first half of 2025 was 14.7%, down 6.8 percentage points from the first half of 2024[21]. - The group experienced a net loss of RMB 12.3 million in the first half of 2025, compared to a net profit of RMB 22.6 million in the first half of 2024[21]. - The loss attributable to the owners of the company in the first half of 2025 was RMB 12.1 million, a decrease of RMB 35.2 million compared to a profit of RMB 23.1 million in the first half of 2024[27]. - The group will not declare an interim dividend for the first half of 2025[17]. - The gross profit for the same period was RMB 60,053,000, down 39.2% from RMB 98,847,000 in 2024[51]. - Operating loss for the six months ended June 30, 2025, was RMB 3,611,000, compared to an operating profit of RMB 46,397,000 in 2024[51]. - The company reported a net loss of RMB 12,068 thousand for the period, compared to a profit of RMB 23,086 thousand in the previous year[57]. Expenses and Cost Management - The group's sales and distribution expenses amounted to RMB 12.1 million, an increase of RMB 2.7 million or 28.7% compared to the first half of 2024[22]. - The group's administrative expenses in the first half of 2025 were RMB 52.9 million, up RMB 3.8 million or 7.7% from the same period in 2024, primarily due to increased personnel costs and R&D expenses related to mainstream and new products[23]. - Financing costs for the period were RMB 12,878,000, compared to RMB 16,693,000 in the same period of 2024, indicating a reduction in financing expenses[83]. - The company reported a decrease in sales costs to RMB 349,924,000 from RMB 360,168,000, reflecting a cost reduction strategy[81]. Market Position and Strategy - The company maintained its market leadership in agar and refined carrageenan production, recognized as the largest global producer of these products as of March 2025[10]. - The company is focused on developing all-natural performance materials, with applications expanding into beauty and home products[10]. - The company plans to change its name to "Green Fresh Biotechnology Company Limited" to better reflect its focus on advanced biotechnology and seaweed products[9]. - The group plans to continue investing in product technology to enhance its product offerings and profitability, particularly in blended products and biodegradable materials[15]. - The company continues to face challenges in the Chinese and European markets, including weak economic conditions and intense price competition[11]. Financial Position and Assets - As of June 30, 2025, the group's cash and bank balances were RMB 106.4 million, a decrease of RMB 35.0 million or 24.8% from December 31, 2024[28]. - The group's net current assets as of June 30, 2025, were RMB 434.5 million, a decrease of RMB 8.4 million or 1.9% from December 31, 2024[29]. - The total bank borrowings of the group as of June 30, 2025, amounted to RMB 530.7 million, with a weighted average interest rate of 3.93%[30]. - Total assets decreased to RMB 1,555,511 thousand as of June 30, 2025, down from RMB 1,572,268 thousand at the end of 2024, representing a decline of approximately 1.06%[54]. - Current assets totaled RMB 1,025,742 thousand, slightly down from RMB 1,038,685 thousand, indicating a decrease of about 1.24%[54]. - Non-current assets amounted to RMB 529,769 thousand, a decrease of 0.15% from RMB 533,583 thousand[54]. - Total liabilities increased to RMB 725,534 thousand, up from RMB 722,126 thousand, reflecting a marginal increase of 0.56%[56]. - Cash and cash equivalents decreased to RMB 81,315 thousand from RMB 120,734 thousand, a significant drop of approximately 32.5%[59]. - The company reported total borrowings of RMB 547,710 thousand as of June 30, 2025, with RMB 436,481 thousand due within one year[76]. Shareholder Information and Corporate Governance - As of June 30, 2025, the total number of issued shares of the company is 874,120,000[125]. - Mr. Chen Jincong holds 161,700,000 shares, representing 18.50% of the company's equity[124]. - Mr. Chen Chuiye holds 161,700,000 shares, also representing 18.50% of the company's equity[124]. - Mr. Guo Dongxu holds 66,150,000 shares, which is 7.57% of the company's equity[124]. - The company has a significant concentration of ownership, with 67.27% of shares held under a concert party agreement[126]. - The beneficial ownership of the company includes 480,000 shares granted under a share incentive plan that have not yet vested as of June 30, 2025[125]. - The largest shareholders include Chuangyu and Yingbo, each holding 161,700,000 shares, representing 18.50%[126]. - The company has a total of 588,000,000 shares under a concert party agreement among major shareholders[126]. - The company adheres to high standards of corporate governance, applying the principles of the corporate governance code[149]. - The board consists of five executive directors and three independent non-executive directors, ensuring a relatively high level of independence[153]. Share Incentive Plans - The company has adopted a share incentive plan to reward selected participants for their contributions to business growth, with a total of 2,580,000 shares granted as of June 30, 2025, of which 1,720,000 shares remain unvested[137]. - The fair value of the shares granted under the incentive plan ranges from HKD 3.27 to HKD 3.50 per share, with a dividend yield of 1.74% and an expected volatility of 43.67%[139]. - The total number of shares granted under the 2024 incentive plan is 3,040,000, with 2,280,000 shares remaining unvested as of June 30, 2025[140]. - The share incentive plan is effective from July 10, 2020, for a duration of ten years[147]. - The company aims to attract and retain contributors beneficial to its long-term development through the stock option plans[132].

致：香港交易及結算所有限公司 公司名稱: 緑新親水膠軆海洋科技有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01084 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人 ...

Group 1 - The core viewpoint of the article is that Green New Biotechnology (01084) reported a decline in revenue and a shift to a loss for the first half of 2025 [1] - The company's revenue for the first half of 2025 was 410 million, representing a year-on-year decrease of 10.7% [1] - The company reported a loss attributable to shareholders of 12.068 million, marking a transition from profit to loss compared to the previous year [1] Group 2 - The loss per share for the company was 0.014 [1] - The decrease in revenue was primarily attributed to a decline in both the sales volume and sales prices of carrageenan and agar during the first half of 2025 [1]